ArticleJACC. Asia2025
Echocardiographic Features of Wild-Type Transthyretin Cardiac Amyloidosis From J-Case: Multicenter Survey in Japan.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis: The Prospective MoRBiDA Study.JACC. Advances · 2026Article
- Prognostic Utility of Regional Longitudinal Strain in Patients With Immunoglobulin Light-Chain Cardiac Amyloidosis: A Report From the J-CASE Multicenter Survey.Circulation reports · 2026Article
- The phenotypic landscape of p.Ala117Ser transthyretin amyloidosis: distinct clinical profiles and outcomes versus wild-type ATTR.BMC cardiovascular disorders · 2025Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWild-type transthyretin cardiac amyloidosis (ATTRwt-CA) occurs at a high prevalence in older patients with left ventricular (LV) hypertrophy. However, detecting ATTRwt-CA using echocardiography is challenging.
objectivesThis study identified echocardiographic findings characterizing ATTRwt-CA compared with monoclonal immunoglobulin light chain cardiac amyloidosis (CA) and hereditary transthyretin CA.
methodsWe conducted a multicenter, retrospective study on the echocardiographic findings characterizing ATTRwt-CA. J-CASE (Japan Cardiac Amyloidosis Survey of typical Echocardiographic findings) analyzed echocardiographic data in 311 patients with histologically proven amyloid deposition in the myocardium and diagnosis of transthyretin CA or monoclonal immunoglobulin light chain CA.
resultsAmong the cohort, 172 patients (55.3%) were diagnosed with ATTRwt-CA. A multiple discriminant analysis revealed that LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of maximal papillary muscle diameter were significant echocardiographic findings characterizing ATTRwt-CA. In addition to the patient backgrounds such as advanced age, male sex, concomitant diabetes mellitus, hyperlipidemia, carpal tunnel syndrome, and paroxysmal atrial fibrillation, the discriminant model, including these echocardiographic findings showed significant discriminant power of ATTRwt-CA from the other subtypes (83.8% accuracy with 86.0% positive predictive value and 81.4% negative predictive value, when the sensitivity and specificity are at their maximum values of the model).
conclusionsIn the J-CASE data set, LV hypertrophy with a more extensive LV mass index but relatively modest interventricular septum thickening and enlargement of papillary muscle diameter significantly characterized ATTRwt-CA. These findings may lead to more accurate screening echocardiography for diagnosing ATTRwt-CA and motivate the subsequent comprehensive clinical diagnostic process, including multimodality imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.